[Economic evaluation of the first TNF-alpha inhibitor therapy in patients with rheumatoid arthritis]

Brodszky V, Pentek M, Majer I, Karpati K, Gulasci L
Record ID 32010001764
Hungarian, English
Authors' recomendations: There is no significant difference in the efficacy and safety figures of the TNF-alfa inhibitors identified at the use of 3mg/kg Remicade (infliximab) and the regular use of Humira (adalimumab) and Enbrel (etanercept). Under the given price structure and financing mechanisms the price of the infliximab is the lowest among the TNF-alfa inhibitors covered by the National Health Insurance Fund Administration budget, while at the same time no significant difference in health gain of these three TNF-alfa inhibitors can be seen. However Remicade could show a higher respond rate at the increased dose setting.
Details
Project Status: Completed
Year Published: 2007
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Hungary
MeSH Terms
  • Arthritis, Rheumatoid
  • Tumor Necrosis Factor-alpha
Contact
Organisation Name: Unit of Health Economics and Technology Assessment in Health Care
Contact Address: Unit of Health Economics and Technology Assessment in Health Care Department of Public Policy and Management Budapest University of Economic Studies 1125 Budapest Fovam ter 8 Budapest HUNGARY Tel: +36 1 218 8197 Fax: +36 1 218 1466
Contact Name: laszlo.gulacsi@uni-corvinus.hu
Contact Email: laszlo.gulacsi@uni-corvinus.hu
Copyright: Unit of Health Economics and Technology Assessment in Health Care (HunHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.